IL-17A Antibody, anti-human, REAfinity™
Synonyms: CTLA-8, IL-17
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
8 Citations6 Images
Clone:
REA1063 | BL168
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for IL-17A Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
APC-Vio 770
FITC
PE
PE-Vio 615
PE-Vio 670
PE-Vio 770
Vio B515
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-118-398, 130-118-244
Description:
Naive CD4+ T cells were isolated from human peripheral blood mononuclear cells (PBMCs). Cells were either left unstimulated (left images) or stimulated with PMA (50 ng/mL) and Ionomycin (1 µg/mL) for six hours. After two hours, brefeldin A (1 µg/mL) was added to the stimulated and to the unstimulated cells. Cells were fixed, permeabilized, and intracellularly stained with Anti-IL-17A antibodies as well as with CD3 antibodies. Cells were then analyzed by flow cytometry using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Extended validation for IL-17A Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1063
CZ8-23G1
high
BL168
high
N49-653
high
EBio64DEC17
low

Cells were incubated with an excess of purified unconjugated IL-17A (REA1063) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for IL-17A. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 4 hours. Cells were stained with a suitable counterstaining and then fixed and permeabilized followed by a staining with IL-17A antibodies. As a control, IL-17A antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD3+/CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for IL-17A Antibody, anti-human, REAfinity™
Overview

Clone REA1063 recognizes human interleukin 17A (IL-17A). IL-17A, also known as CTLA8, is a member of the IL-17 family (IL-17A–F), is a disulfide-linked homodimeric glycoprotein. IL-17A is produced by CD4+ T helper (Tʜ) cells, a third T cell subset termed Tʜ17, which secrete also cytokines such as IL-17F and IL-22 and express the natural killer (NK) cell marker CD161. IL-17A secretion has also been described for other cell types, such as CD8+ memory T cells. Furthermore, intracellular IL-17A has also been detected in eosinophils, neutrophils, and blood monocytes. Emerging data about Tʜ17 cells suggest that these cells are involved in the recruitment of neutrophils to control early stages of infections to a number of pathogens, such as extracellular bacteria and fungi. IL-17A and Tʜ17 cells have been shown to play an important role in immune-mediated diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, asthma, inflammatory bowel diseases, and other immune-mediated inflammatory conditions.

Depending on the cytokine milieu present at time of the initial engagement, CD4+ naive T cells can differentiate into various subsets (Tʜ1, Tʜ2, and Tʜ17). For the differentiation into Tʜ17 cells several cytokines have been described, including TGF-β, IL-1β, IL-6, IL-21, and IL-23. RORγt was identified as the master regulator gene for Tʜ17 cells.

Additional information: Clone REA1063 displays negligible binding to Fc receptors.

Alternative names

CTLA-8, IL-17

Detailed product information

Technical specifications

Clone
REA1063
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
IL-17A
Molecular mass of antigen [kDa]
15
Distribution of antigen
monocytes, T cells, CD4+ T cells, CD8+ T cells, eosinophils, neutrophils, Th17 cells
Entrez Gene ID
RRID
AB_2751503, AB_2751468, AB_2751499, AB_2751505, AB_2751470, AB_2751504, AB_2751469, AB_2751501, AB_2751466, AB_2751467, AB_2751471, AB_2751502, AB_2751500, AB_2751465

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for IL-17A Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?